account2009 period included $3.0 million related to the sale of certain excipients used in REMOXY(R) to King Pharmaceuticals in 2008 and the first quarter of 2009, all of which was recognized upon the execution of the long term supply agreement between us and...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to DURECT Corporation Announces Third Quarter 2009 Financial Results
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
